title: Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
abstract: BACKGROUND
  Facial lipoatrophy is a crucial problem of HIV-infected patients undergoing highly active antiretroviral therapy (HAART). Poly-L-lactic acid (PLA), provided as New-Fill/Sculptra, is known as one possible treatment option. In 2004 PLA was approved by the FDA as Sculptra for the treatment of lipoatrophy of the face in HIV-infected patients. While the first trials demonstrated relevant efficacy, this was to some extent linked to unwanted effects. As the depth of injection was considered relevant in this context, the application modalities of the preparation were changed. The preparation was to be injected more deeply into subcutaneous tissue, after increased dilution.
  
  
  METHODS
  To test this approach we performed a pilot study following the new recommendations in 14 patients.
  
  
  RESULTS
  While the efficacy turned out to be about the same, tolerability was markedly improved. The increase in facial dermal thickness was particularly obvious in those patients who had suffered from lipoatrophy for a comparatively small period of time.
  
  
  CONCLUSIONS
  With the new recommendations to dilute PLA powder and to inject it into the deeper subcutaneous tissue nodule formation is a minor problem. However, good treatment results can only be achieved if lipoatrophy is not too intense; treatment intervals should be about 2-3 weeks.
authors.affiliation: Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany. c.borelli@med.uni-muenchen.de
authors.forename: C
authors.initials: C
authors.lastname: Borelli
authors.forename: C
authors.initials: C
authors.lastname: Kunte
authors.forename: P
authors.initials: P
authors.lastname: Weisenseel
authors.forename: E
authors.initials: E
authors.lastname: Thoma-Greber
authors.forename: H C
authors.initials: HC
authors.lastname: Korting
authors.forename: B
authors.initials: B
authors.lastname: Konz
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage / Q000627:therapeutic use*; D012885:Skinfold Thickness
chemical_list: D001672:Biocompatible Materials; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide)